http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102836446-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1fefd66fdbc3870bbaa8e5a4f87bdb0a |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2012-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_693b1d47f8ce47b2d94c8c3119a16543 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_449cfb4b9d96b11a01654478cb93128f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce134e9f7b8af7a47b46882ea57705c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d54f95fefab7f819e9ab7f583784807e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6bf8da23f01982c73d4658f79ca71e67 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4294733fa2964dc959ab04d2fa2e320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa9dce836b8284b6997ef5f6590b5107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_718e1b02f8ffdb6d75df887989557bba http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c87fbd42957bd10bc76d1642aefb9755 |
| publicationDate | 2014-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102836446-B |
| titleOfInvention | In-vivo phase transition tumor targeted nanobubble, its preparation method and application |
| abstract | Belonging to the technical field of biomedicine, the invention specifically relates to an in-vivo phase transition tumor targeted nanobubble, its preparation method and application. The nanobubble takes a polyphosphate-polyester copolymer of a coupling tumor targeting factor as a coating material, adopts perfluoropentane able to undergo liquid-gas phase transition in vivo as a bubble core filling material, and is prepared by a pre-multiple emulsion-hollow membrane tube emulsification method. When the nanobubble enters the body, the liquid perfluoropentane undergoes liquid-gas phase transition at body temperature to form a gas-containing nanobubble. By means of the specific combination of a targeting factor and a tumor cell, the nanobubble can concentrate a tumor focus part, thus improving the tumor focus ultrasonic imaging effect. The nanobubble can be loaded with an MRI contrast agent to improve the tumor focus MRI imaging effect. The nanobubble can also be loaded with an antitumor drug and used for targeted treatment of tumors, thus being a novel diagnosis-treatment integrated multifunctional imageological nano-contrast agent. |
| priorityDate | 2012-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 137.